Analyst Research

Report Title Price
Provider: S&P Capital IQ Quantitative Report
$127.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

InterMune Inc's Esbriet (pirfenidone) Receives Positive Final Appraisal Determination from NICE for Idiopathic Pulmonary Fibrosis


Wednesday, 20 Mar 2013 09:34pm EDT 

InterMune Inc announced that the National Institute for Health and Clinical Excellence (NICE), the health technology appraisal body in England and Wales, has issued its Final Appraisal Determination (FAD) recommending Esbriet (pirfenidone) for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF). The Company estimates that approximately 6,100 to 9,500 mild-to-moderate IPF patients are living with IPF in England and Wales. The NICE Appraisal Committee recommended pirfenidone as an option for treating IPF patients whose predicted forced vital capacity (FVC) is between 50 percent and 80 percent at the initiation of therapy. Treatment with pirfenidone for these patients should be discontinued if there is evidence of disease progression (as defined by a decline in percent predicted FVC of 10 percent or more within any 12-month period). Based on the clinical study experience with Esbriet, the company expects that between 10 and 15 percent of patients could meet this definition of disease progression in a given 12-month period. The FAD further recommends the prescription of Esbriet for as long as InterMune makes the Patient Access Scheme (PAS) available. The PAS is a confidential pricing and access agreement with the UK's Department of Health. The NHS list price for Esbriet is £26,100 per full year of treatment. At current rates of exchange this is equivalent to roughly €30,140 and $39,350 per patient per year. 

Company Quote

73.45
0.24 +0.33%
29 Aug 2014